naltrexone has been researched along with Autoimmune Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atanaskova Mesinkovska, N | 1 |
| Bonneau, RH; Donahue, RN; McLaughlin, PJ; Zagon, IS | 1 |
| McLaughlin, PJ; Zagon, IS | 1 |
| Blum, HE; Kreisel, W; Opitz, OG; Thimme, R | 1 |
| Aoki, CA; Gershwin, ME; Itoh, M; Kato, T; Kawashima, Y; Kikuchi, K; Kurokawa, T; Miyakawa, H; Nakao, K; Okano, K; Umeuchi, H | 1 |
2 review(s) available for naltrexone and Autoimmune Disease
| Article | Year |
|---|---|
Emerging Unconventional Therapies for Alopecia Areata.
Topics: Alopecia Areata; Autoimmune Diseases; Cryotherapy; Histamine Antagonists; Humans; Naltrexone; Narcotic Antagonists | 2018 |
[Cholestatic liver diseases].
Topics: Anti-Bacterial Agents; Antibodies, Antineutrophil Cytoplasmic; Anticholesteremic Agents; Antipruritics; Autoimmune Diseases; Bile Ducts; Cholagogues and Choleretics; Cholangiography; Cholangitis; Cholangitis, Sclerosing; Cholestasis; Cholestyramine Resin; Clinical Enzyme Tests; Diagnosis, Differential; Hepatitis, Autoimmune; Humans; Immunosuppression Therapy; Inflammatory Bowel Diseases; Liver Cirrhosis; Liver Cirrhosis, Biliary; Liver Transplantation; Naloxone; Naltrexone; Narcotic Antagonists; Ondansetron; Plasmapheresis; Ursodeoxycholic Acid | 2004 |
4 other study(ies) available for naltrexone and Autoimmune Disease
| Article | Year |
|---|---|
T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
Topics: Animals; Autoimmune Diseases; Cell Proliferation; Cells, Cultured; Enkephalin, Methionine; Immunosuppression Therapy; Male; Mice; Mice, Inbred C57BL; Naltrexone; Receptors, Opioid; RNA, Small Interfering; T-Lymphocytes | 2011 |
ALSUntangled No. 8: Low dose naltrexone for ALS.
Topics: Amyotrophic Lateral Sclerosis; Autoimmune Diseases; Dose-Response Relationship, Drug; Humans; Immune System; Immunologic Factors; Internet; Naltrexone; Neuroimmunomodulation; Neuroprotective Agents | 2011 |
The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
Topics: Animals; Antineoplastic Agents; Autoimmune Diseases; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Diabetes Complications; Enkephalin, Methionine; Epithelium; Homeostasis; Humans; Lymphocytes; Naltrexone; Narcotic Antagonists; Neoplasms; Receptors, Opioid; Wound Healing | 2012 |
Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride.
Topics: Age Factors; Animals; Antipruritics; Autoimmune Diseases; Behavior, Animal; Chlorpheniramine; Dermis; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Immunoglobulin E; Immunoglobulin G; Male; Mice; Mice, Inbred ICR; Mice, Inbred MRL lpr; Mice, Inbred Strains; Morphinans; Naltrexone; Pruritus; Receptors, Opioid, kappa; Sex Factors; Spiro Compounds | 2005 |